Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial
Authors:
- Ellen GormanEGEllen Gorman
- Manu Shankar-HariMSManu Shankar-Hari
- Phil HopkinsPHPhil Hopkins
- William S. TunnicliffeWTWilliam S. Tunnicliffe
- Gavin D. PerkinsGPGavin D. Perkins
- Jonathan SilversidesJSJonathan Silversides
- Peter McGuiganPMPeter McGuigan
- Colette JacksonCJColette Jackson
- Roisin BoyleRBRoisin Boyle
- Jamie McFerranJMJamie McFerran
- Cliona McDowellCMCliona McDowell
- Christina CampbellCCChristina Campbell
Open Access
- 13 May 2022
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-15
Abstract
Background: Mesenchymal stromal cells (MSCs) may be of benefit in ARDS due to immunomodulatory and reparative properties. This trial investigates a novel CD362 enriched umbilical cord derived MSC product (REALIST ORBCEL-C), produced to Good Manufacturing Practice standards, in patients with moderate to severe ARDS due to COVID-19 and ARDS due to other causes. Methods: Phase 1 is a multicentre open-label dose-escalation pilot trial. Patients will receive a single infusion of REALIST ORBCEL-C (100 × 106 cells, 200 × 106 cells or 400 × 106 cells) in a 3 + 3 design. Phase 2 is a multicentre randomised, triple blind, allocation concealed placebo-controlled trial. Two cohorts of patients, with ARDS due to COVID-19 or ARDS due to other causes, will be recruited and randomised 1:1 to receive either a single infusion of REALIST ORBCEL-C (400 × 106 cells or maximal tolerated dose in phase 1) or placebo. Planned recruitment to each cohort is 60 patients. The primary safety outcome is the incidence of serious adverse events. The primary efficacy outcome is oxygenation index at day 7. The trial will be reported according to the Consolidated Standards for Reporting Trials (CONSORT 2010) statement. Discussion: The development and manufacture of an advanced therapy medicinal product to Good Manufacturing Practice standards within NHS infrastructure are discussed, including challenges encountered during the early stages of trial set up. The rationale to include a separate cohort of patients with ARDS due to COVID-19 in phase 2 of the trial is outlined. Trial registration: ClinicalTrials.gov NCT03042143. Registered on 3 February 2017. EudraCT Number 2017-000584-33Keywords
Funding Information
- public health agency research and development division northern ireland
- Wellcome Trust (106939/Z/15/Z)
This publication has 56 references indexed in Scilit:
- Early phase clinical trials to identify optimal dosing and safetyMolecular Oncology, 2014
- Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot studyRespiratory Research, 2014
- MSC-Based Product Characterization for Clinical Trials: An FDA PerspectiveCell Stem Cell, 2014
- Acute Respiratory Distress SyndromeJAMA, 2012
- Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytesAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2012
- Functional Disability 5 Years after Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2011
- A Randomized Clinical Trial of Hydroxymethylglutaryl– Coenzyme A Reductase Inhibition for Acute Lung Injury (The HARP Study)American Journal of Respiratory and Critical Care Medicine, 2011
- Simvastatin Decreases Lipopolysaccharide-induced Pulmonary Inflammation in Healthy VolunteersAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Predictors of mortality in acute lung injury during the era of lung protective ventilationThorax, 2008
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006